| Hu, Yu |
EFFECT, NCT05902078: Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis |
|
|
| Recruiting | 4 | 300 | RoW | Eldecalcitol capsules, Edirol, Calcitriol capsules, Haidewei | Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Chugai Pharma China Co., Ltd. | Low Bone Mineral Density, Postmenopausal Osteoporosis | 06/25 | 12/25 | | |
NCT05020392: Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma |
|
|
| Recruiting | 3 | 24 | RoW | BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells, Fludarabine-based chemotherapy + CAR-T-CD19 Cells | Wuhan Union Hospital, China, Wuhan Si'an Medical Technology Co., Ltd | Diffuse Large B Cell Lymphoma, Burkitt Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | 10/23 | 10/24 | | |
| Active, not recruiting | 3 | 194 | Europe, Canada, Japan, US, RoW | Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo | Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc. | Immune Thrombocytopenia | 06/25 | 11/26 | | |
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
|
|
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Depemokimab, Placebo | GlaxoSmithKline | Hypereosinophilic Syndrome | 02/26 | 03/26 | | |
NCT06082102: Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma |
|
|
| Recruiting | 3 | 324 | RoW | Orelabrutinib, Lenalidomide, Rituximab, Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Relapsed/Refractory Marginal Zone Lymphoma | 08/27 | 02/30 | | |
| Recruiting | 2 | 50 | RoW | Selinexor (80mg/d), ATG-010, Selinexor (100mg/d), Pegylated liposomal doxorubicin, PLD, Dexamethasone, Dex, Cyclophosphamide, CTX | Chunyan Sun, MD | Multiple Myeloma | 12/24 | 12/24 | | |
NCT05269940: A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies |
|
|
| Completed | 1/2 | 40 | RoW | ZX-101A | Nanjing Zenshine Pharmaceuticals | Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma, CLL/SLL | 01/23 | 07/24 | | |
| Recruiting | 1/2 | 80 | RoW | TQB3454 Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 06/25 | 12/25 | | |
ESTEVS-I/II, NCT06677255: A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment |
|
|
| Not yet recruiting | 1/2 | 149 | RoW | VUM02 Injection (UC-MSCs)+BAT, The control group with Best Available Therapy (BAT), Control group | Wuhan Optics Valley Vcanbiopharma Co., Ltd. | Steroid-refractory Acute Graft-versus-host Disease | 12/26 | 12/28 | | |
NCT04007978: Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies |
|
|
| Recruiting | 1 | 50 | RoW | Third generation CAR-T cells | Wuhan Union Hospital, China, Wuhan Bio-Raid Biotechnology Co., Ltd. | B Cell Lymphoma, Acute Lymphoblastic Leukemia | 06/22 | 12/22 | | |
NCT04008251: Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies |
|
|
| Recruiting | 1 | 10 | RoW | Second generation humanized CAR-T cells | Wuhan Sian Medical Technology Co., Ltd, Wuhan Union Hospital, China, Jingzhou Central Hospital, Xiangyang Central Hospital, People Hospital Of Yichang | Acute Lymphoblastic Leukemia, B Cell Lymphoma | 07/22 | 12/22 | | |
NCT04008394: Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies |
|
|
| Recruiting | 1 | 50 | RoW | Anti-CD30 CAR T cells | Wuhan Union Hospital, China, Wuhan Bio-Raid Biotechnology Co, Ltd. China | Adult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, NK/T-cell Lymphoma, Peripheral T Cell Lymphoma, Hodgkin Lymphoma | 07/22 | 01/23 | | |
NCT04008381: Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia |
|
|
| Recruiting | 1 | 38 | RoW | Ex-vivo Expanded γδ T Lymphocytes | Wuhan Union Hospital, China, Jinan University, China | Acute Myeloid Leukemia | 07/22 | 01/23 | | |
NCT04796675: Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies |
|
|
| Recruiting | 1 | 27 | RoW | Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells | Wuhan Union Hospital, China, Shanghai Simnova Biotechnology Co.,Ltd. | Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin's Lymphoma | 03/23 | 03/24 | | |
NCT06206902: F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma |
|
|
| Recruiting | 1 | 55 | RoW | After preconditioning with chemotherapy, F01 will be evaluated. | Shanghai Simnova Biotechnology Co.,Ltd., Wuhan Union Hospital, China | Non-Hodgkin's Lymphoma | 01/25 | 12/25 | | |
NCT05367700: A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. |
|
|
| Recruiting | 1 | 108 | RoW | HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | CML, Chronic Phase, CML, Accelerated Phase | 12/24 | 09/26 | | |
NCT05765006: CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 24 | RoW | Relma-cel | Shanghai Ming Ju Biotechnology Co., Ltd. | Systemic Lupus Erythematosus | 12/24 | 12/25 | | |
NCT05779150: Efficacy of CeraVe® Moisturizing Cream on Skin Pruritus in Elderly Patients |
|
|
| Recruiting | N/A | 50 | RoW | CeraVe® Moisturising Cream, Standard Cream | Shanghai Zhongshan Hospital | Pruritus | 06/23 | 02/24 | | |
NCT05852028: A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 250 | RoW | Selinexor, XPO1 inhibitor | Ruijin Hospital | Lymphoma, DLBCL, T Cell Lymphoma | 10/24 | 10/25 | | |
| Yamaguchi, Masaki |
| Active, not recruiting | 3 | 194 | Europe, Canada, Japan, US, RoW | Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo | Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc. | Immune Thrombocytopenia | 06/25 | 11/26 | | |
